FAQ/Help |
Calendar |
Search |
Today's Posts |
11-29-2011, 11:52 PM | #1 | |||
|
||||
Senior Member
|
The company said it plans to start clinical studies of CVT-301 by the end of 2011...
CVT-301 aims to give rapid, consistent and durable relief from debilitating motor fluctuations associated with Parkinson’s disease. Civitas is developing a proprietary platform for inhaled therapeutics based on technology and underlying assets bought from Alkermes, including a large amount of intellectual property, a set of development stage pipeline candidates, specialized pulmonary equipment and a commercial-scale manufacturing plant. Glenn Batchelder, CEO of Civitas, said the award from the foundation “provides important validation of our vision to improve Parkinson’s patients’ lives with an inhaled L-dopa therapeutic by overcoming the historical challenges in developing a better way to administer L-dopa.” http://www.masshightech.com/stories/...Fox-grant.html
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
"Thanks for this!" says: | soccertese (11-30-2011), stevem53 (11-30-2011) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Jefferson researcher awarded Landenberger Foundation grant for ALS research | ALS News & Research | |||
ALS Therapy Development Institute Awarded $1M Grant | ALS News & Research | |||
Vanderbilt Awarded $4.4 Million by the Michael J. Fox | Parkinson's Disease |